Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged Non-Small Cell Lung Cancer with brain metastases

In-frame fusion KIF5B (the-kinesin-family-5B-gene)-RET transcripts have been characterized in 1–2% of non-small cell lung cancers and are known oncogenic drivers. The RET tyrosine kinase inhibitor, vandetanib, suppresses fusion-induced, anchorage-independent growth activity. In vitro studies have sh...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lung Cancer
Asıl Yazarlar: Subbiah, Vivek, Berry, Jenny, Roxas, Michael, Guha-Thakurta, Nandita, Subbiah, Ishwaria Mohan, Ali, Siraj M., McMahon, Caitlin, Miller, Vincent, Cascone, Tina, Pai, Shobha, Tang, Zhenya, Heymach, John V.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998046/
https://ncbi.nlm.nih.gov/pubmed/25982012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2015.04.004
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller